CTRI/2021/09/036217尚未招募1 期
An institutional phase I/II study to evaluate safety and efficacy of high dose weekly hypofractionated palliative breast radiotherapy in fungating advanced unresectable or metastatic breast cancer
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)Histopathologically proven primary breast cancer deemed surgically inoperable
- •2)Clinically or radiologically T4 disease staged based on 8th Ed TNM staging system,
- •3)Age >18years,
- •4)Eastern co-operative oncology group performance score of <=3.
排除标准
- •1) male breast cancer
- •2) history of second malignancy
- •3) prior breast or thoracic irradiation
研究者
相似试验
招募中
1 期
A Phase 1b, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of ST-617 for the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for Head and Neck CancerACTRN12620000541909PSI CRO Australia Pty. Ltd.134
进行中（未招募）
不适用
Safety and Effect of the Histone Deacetylase Inhibitor Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV ReservoirHIV-infectionMedDRA version: 17.1Level: LLTClassification code 10008919Term: Chronic HIV infectionSystem Organ Class: 100000004862EUCTR2013-004747-23-DKBionor Pharma ASA
已完成
2 期
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participants with NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer (study 208471)lung cancerNL-OMON52531GlaxoSmithKline9
进行中（未招募）
1 期
A study of NY-ESO-1 T-cells (GSK3377794) alone and in combination with Pembrolizumab in NSCLC patients.EUCTR2018-003949-42-NLGlaxoSmithKline Research & Development Ltd54
进行中（未招募）
1 期
A Study of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA SignalingSolid Tumors Dependent on KIT or PDGFRA SignalingMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2020-005234-15-ITBLUEPRINT MEDICINES CORPORATIO37